The present invention provides methods of administering a clotting factor by a fixed dosing regimen； methods of reducing, ameliorating, or preventing one or more symptoms of a bleeding disease or disorder； and a kit comprising a dotting factor useful for a fixed dosing regimen. While plasma-derived and recombinant clotting factor products allow hemophilia patients to live longer and healthier, hemophilia still remains one of the most costly and complex conditions to manage.
